UNSPSC 51461501: Centella asiatica extract

This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7M867G6T1U, although the US FDA Substance Registration System (SRS) identifies several varieties and preparations under UNIIs J02K2IV2PB, 8MXU1P42J0, and 6810070TYD, the source product of which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 29612 Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Apiales, Family Apiaceae, Genus Centella L., Species Centella asiatica, more commonly known as SPADELEAF or as here, CENTELLA ASIATICA.

UNSPSC 51461501 Centella asiatica extract is a Commodity code that captures botanical and plant-derived pharmaceutical ingredients supplied to state and local government health systems, correctional facilities, and public health programs. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body active under this code in recent procurement, consolidating demand across participating state agencies and local government facilities in Minnesota and Oregon. The scope of work encompasses supply of FDA-compliant generic multi-source pharmaceuticals and over-the-counter products with specified National Drug Codes (NDC), SKUs, UPCs, and manufacturing certifications. Vendors must maintain current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance, establish contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), and support electronic data interchange (EDI) capabilities. Products must be available in the marketplace by May 15, 2026, and maintain expiration dates of at least one year from manufacture with a minimum six-month shelf life.

MMCAP issued a Request for Proposal (S1070000015802) for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. Award decisions will be weighted on price competitiveness (75 percent), fixed pricing for the contract term (10 percent), compliance with administrative fee and EDI requirements (5 percent each), and agreement to a 3 percent administrative fee (5 percent). The contract term is two years for new vendors, with optional extensions at MMCAP's discretion, while incumbent vendors' amendments extend through June 30, 2028. Vendors must maintain comprehensive insurance coverage including commercial general liability of $5 million per occurrence and network security and privacy liability of $2 million. MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations, product availability, and member-specific needs.